Attached files
| file | filename |
|---|---|
| 8-K - 8-K - ENZON PHARMACEUTICALS, INC. | v326929_8k.htm |
EXHIBIT 99.1
| Investor Contact: | Andrea Rabney | ||
| Argot Partners | |||
| 212.600.1902 | |||
| andrea@argotpartners.com |
| Media Contact: | Eliza Schleifstein | ||
| Argot Partners | |||
| 212.600.1902 | |||
| eliza@argotpartners.com |
Enzon Reports Third Quarter 2012 Results
PISCATAWAY, N.J. – October 31, 2012 — Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for the third quarter of 2012. Enzon reported net income of $4.2 million, or $0.08 diluted earnings per share, for the third quarter of 2012, as compared to a net loss of $9.1 million, or $0.19 diluted loss per share, for the third quarter of 2011.
Summary of Financial Results
Royalty Revenue
Royalty revenue for the three months ended September 30, 2012 increased 7% to $10.9 million, as compared to $10.2 million for the three months ended September 30, 2011. This royalty revenue is the result of sales generated from marketed products that use the Company’s proprietary customized PEGylation linker technology. Sales of PEGINTRON by Merck continued to constitute the most significant source of royalty revenues for the Company. Royalty revenue was flat at $31.0 million for the nine months ended September 30, 2012 compared to $31.1 million during the same period of 2011.
Research and Development
The Company’s pipeline research and development expenses decreased 62% to $4.0 million for the three months ended September 30, 2012, as compared to $10.4 million for the three months ended September 30, 2011. The pipeline consists of the following clinical programs: PEG-SN38 and mRNA antagonists targeting the Androgen Receptor (AR), Hypoxia-Inducible Factor-1a (HIF-1a) and Survivin. In addition, the Company has other novel LNA targets in various stages of preclinical research. The Company continues to employ its Customized Linker Technology® on preclinical collaborative partnership programs. Clinical development expenses have declined in 2012 compared to the same three month period of 2011 due to the completion of enrollment in both of our PEG-SN38 Phase II clinical trials, as well as our Phase I clinical trials for the HIF-1α and Survivin mRNA antagonists. At this time, we do not intend to proceed with the clinical development of the Survivin mRNA antagonist.
General and Administrative
General and administrative expenses decreased approximately 22% to $3.2 million for the three months ended September 30, 2012, as compared to $4.1 million for the three months ended September 30, 2011. This decrease was largely the result of several restructuring programs implemented over the past year, as well as the Company’s on-going cost containment efforts.
Cash and Investments
Total cash reserves, which consist of cash, cash equivalents and marketable securities, were $288.7 million as of September 30, 2012, as compared to $323.3 million as of December 31, 2011. The decrease was primarily attributable to the resumption of the share repurchase program and the repurchase of outstanding notes payable. For the three months ended September 30, 2012, the Company repurchased approximately 2.4 million shares of its outstanding common stock at a cost of $16.2 million. During the nine months ended September 30, 2012, the Company repurchased a total of 3.2 million shares of its outstanding common stock at a cost of $21.5 million. Since the inception of the share repurchase program, Enzon has purchased approximately 14.6 million shares of its outstanding common stock at a cumulative cost of $143.0 million.
Recent Highlights
| · | In July, at the 39th Annual Meeting & Exposition of the Controlled Release Society, Enzon presented data from pre-clinical studies on the controlled release of human interferon-beta-1b (IFN-β-1b) and anti-TNF-a antibody fragment (FAB) through releasable PEGylation technology. The data demonstrated how releasable PEGylation opens new opportunities to capture the inherent benefit of PEG technology, particularly with compounds that are not suitable for permanent PEGylation. |
| · | In September, at the 2012 World Congress and Expo on Biowaivers and Biosimilars, Enzon presented an overview of PEGylation, its Customized Linker Technology®, and its potential to create or enhance biobetter and biosimilar therapeutics by extending the benefit of this proprietary technology to a wider range of therapeutic molecules. |
About Enzon
Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to the research and development of innovative therapeutics for patients with high unmet medical need. Enzon's drug-development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology®) and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. Enzon currently has four compounds in human clinical development and multiple novel mRNA antagonists in preclinical research. Enzon receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its proprietary Customized Linker Technology. Further information about Enzon and this press release can be found on the Company's website at www.enzon.com.
Forward-Looking Statements
This press release contains, or may contain, forward-looking statements within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements that are purely historical, are forward-looking statements, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions.
Such forward-looking statements are based upon management’s present expectations, objectives, anticipation, plans, hopes, beliefs, intentions or strategies regarding the future and are subject to known and unknown risks and uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward-looking statements, including, but not limited to: (i) the timing, success and cost of clinical studies for Enzon’s product candidates, (ii) the ability to obtain regulatory approval of Enzon’s product candidates, (iii) Enzon’s ability to obtain a strategic partner to develop and commercialize PEG-SN 38, (iv) Enzon’s ability to obtain the funding necessary to develop its product candidates, (v) market acceptance and demand for Enzon’s product candidates, and (vi) the impact of competitive products, pricing and technology. A more detailed discussion of these and other factors that could affect results is contained in Enzon’s filings with the U.S. Securities and Exchange Commission, including Enzon’s Annual Report on Form 10-K for the year ended December 31, 2011. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.
Enzon Pharmaceuticals, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income (Loss)
(Unaudited; In thousands, except per share amounts)
| Three months ended | ||||||||
| September 30, | ||||||||
| 2012 | 2011 | |||||||
| Revenues: | ||||||||
| Royalties | $ | 10,919 | $ | 10,207 | ||||
| Sale of in-process research and development | - | - | ||||||
| Contract research and development | - | 54 | ||||||
| Miscellaneous income | 202 | 179 | ||||||
| Total Revenues | 11,121 | 10,440 | ||||||
| Operating Expenses: | ||||||||
| Research and development - pipeline | 3,954 | 10,436 | ||||||
| Research and development - specialty and contracted services | 10 | 47 | ||||||
| General and administrative | 3,209 | 4,102 | ||||||
| General and administrative - contracted services | - | 2 | ||||||
| Restructuring charges | (113 | ) | 3,616 | |||||
| Total Operating Expenses | 7,060 | 18,203 | ||||||
| Operating Income (Loss) | 4,061 | (7,763 | ) | |||||
| Other Income (Expense): | ||||||||
| Investment income, net | 1,386 | 407 | ||||||
| Interest expense | (1,274 | ) | (1,480 | ) | ||||
| Other, net | 2 | (69 | ) | |||||
| Total Other Income (Expense) | 114 | (1,142 | ) | |||||
| Income (loss) before income tax expense | 4,175 | (8,905 | ) | |||||
| Income tax expense | - | 200 | ||||||
| Net Income (Loss) | $ | 4,175 | $ | (9,105 | ) | |||
| Basic earnings (loss) per common share | $ | 0.09 | $ | (0.19 | ) | |||
| Diluted earnings (loss) per common share | $ | 0.08 | $ | (0.19 | ) | |||
| Weighted-average shares outstanding - basic | 46,387 | 48,729 | ||||||
| Weighted-average shares outstanding - diluted | 58,563 | 48,729 | ||||||
| Other Comprehensive Loss: | ||||||||
| Available-for-sale marketable securities: | ||||||||
| Unrealized holding gains (losses) arising during period | $ | 590 | $ | (323 | ) | |||
| Reclassification adjustment for realized gains on sales included in net income (loss) | (979 | ) | (139 | ) | ||||
| Total Other Comprehensive Loss | (389 | ) | (462 | ) | ||||
| Comprehensive Income (Loss) | $ | 3,786 | $ | (9,567 | ) | |||
Enzon Pharmaceuticals, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited; In thousands)
| September 30, | December 31, | |||||||
| 2012 | 2011 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 140,946 | $ | 104,324 | ||||
| Marketable securities | 137,492 | 58,188 | ||||||
| Other current assets | 2,236 | 2,749 | ||||||
| Total current assets | 280,674 | 165,261 | ||||||
| Property and equipment, net | 13,323 | 16,802 | ||||||
| Marketable securities | 10,299 | 160,779 | ||||||
| Other assets | 172 | 367 | ||||||
| Total Assets | $ | 304,468 | $ | 343,209 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,058 | $ | 1,572 | ||||
| Accrued expenses and other current liabilities | 7,394 | 13,692 | ||||||
| Notes payable | 115,849 | - | ||||||
| Total current liabilities | 124,301 | 15,264 | ||||||
| Notes payable | - | 129,499 | ||||||
| Other liabilities | 452 | 1,265 | ||||||
| Total Liabilities | $ | 124,753 | $ | 146,028 | ||||
| Total Stockholders' Equity | $ | 179,715 | $ | 197,181 | ||||
| Total Liabilities and Stockholders' Equity | $ | 304,468 | $ | 343,209 | ||||